Sanofi completes $470m Vigil acquisition

Big pharma plans Phase 2 Alzheimer’s trial of Vigil’s oral TREM2 agonist designed to convert microglia into their neuroprotective state. Pharma giant Sanofi has completed its acquisition of Vigil Neuroscience, aiming to bolster its early-stage neurology portfolio with assets focused on neurodegenerative diseases. The deal will see Vigil’s lead drug candidate, VG-3927, an oral small-molecule TREM2 […] The post Sanofi completes $470m Vigil acquisition appeared first on Longevity.Technology.